Infinity Pharmaceuticals ipi.com


Public list: BIO 2016 (619) Pharma Startups (4740)

Infinity Pharmaceuticals is a drug discovery company that is developing and integrating approaches and capabilities in synthetic chemistry, chemical genetics, informatics, and biological screening.

Infinity Pharmaceuticals is a drug discovery company that is developing and integrating approaches and capabilities in synthetic chemistry, chemical genetics, informatics, and biological screening.

Company (IPO / Went public)

Phone: 617-453-1000

Fax:

784 Memorial Drive

Cambridge, 02139
Massachusetts, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Infinity Pharmaceuticals $132.2M Apr 12, 2006
See all 17 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Infinity Pharmaceuticals Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 1 investors

Board Members

Competitors

Company Status Description Investors

Ensemble Therapeutics

Cambridge, Massachusetts, United States
Dead / InactiveEnsemble Therapeutics is an early stage company focused on translating fundamental innovation in chemical discovery into products that address needs life science, materials, electronics, and chemical markets.Login to see details

Enanta Pharmaceuticals

Watertown, Massachusetts, United States
IPO / Went publicEnanta Pharmaceuticals is a research and development-focused biotechnology companythat uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field. The company is discovering and developing inhibitors designed for use against the hepatitis C virus, or HCV. These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes - protease (partnered with AbbVie, the former research-based pharmaceutical bu...Show allLogin to see details
See all 17 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Cyclopamine analogs Oct 10, 2016 Apr 24, 2018 Patent
Methods of treating a fatty acid amide hydrolase-mediated condition Feb 25, 2015 Apr 24, 2018 Patent
Transfer hydrogenation of cyclopamine analogs Jun 23, 2016 Jan 30, 2018 Patent
Enzymatic transamination of cyclopamine analogs Feb 25, 2016 Jan 30, 2018 Patent
Solid forms of (s)-3-(1-(9h-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2h)-one and methods of use thereof Feb 04, 2016 Dec 12, 2017 Patent
See all 80 patents